Alavi, JB, Schoenfeld, D, Skeel, RT, Kirkwood, R, Tsung, L, Marsh, JC. Phase II trial of spirogermanium and vindesine in malignant glioma. „Am J Clin Oncol”. 12. 1, s. 8-10, 1989. PMID: 2912024.
Kuebler, JP, Tormey, DC, Harper, GR, et al. Phase II study of spirogermanium in advanced breast cancer. „Cancer Treat Rep”. 68. 12, s. 1515-1516, 1984. PMID: 6509457.
Lad, TE, Blough, RR, Evrard, M, et al. Phase II trial of spirogermanium in advanced non-small cell lung cancer. An Illinois Cancer Council Study. „Invest New Drugs”. 7. 2-3, s. 223-224, 1989. PMID: 2551841.
Novik, Y, Ryan, LM, Haller, DG, et al. Phase II protocol for the evaluation of new treatments in patients with advanced gastric carcinoma: results of ECOG 5282. „Med Oncol”. 16. 4, s. 261-266, 1999. PMID: 10618689.
Badger AM, Schwartz DA, Picker DH, Dorman JW, Bradley FC, Cheeseman EN, DiMartino MJ, Hanna N, Mirabelli CK. Antiarthritic and suppressor cell inducing activity of azaspiranes: structure-function relationships of a novel class of immunomodulatory agents. „J Med Chem”. 33. 11, s. 2963-2970, 1990. PMID: 2146392.
Tanowitz, HB, Brennessel, DJ, Baum, SG, Salgo, MP, Braunstein, V, Wittner, M. Trypanosoma cruzi: inhibition by spirogermanium hydrochloride. „Exp Parasitol”. 64. 1, s. 57-63, 1987. PMID: 3301388.
